R&D News | pharmaphorum

News

Sofinnova closes new fund and backs a trio of new biotechs

Sofinnova Partners has raised €165m for its new biotech fund and backed three startups working on Alzheimer's, fibrotic diseases, and cell therapies.

News

AstraZeneca buys cell therapy biotech for up to $1bn

AstraZeneca plans to acquire Belgian in vivo cell therapy biotech EsoBiotec and has signed a pair of licensing deals with drug delivery firm Alteogen.

News

Vertanical's chief executive, Dr Clemens Fischer

Vertanical's cannabis-based painkiller hits target in trials

A cannabis-derived drug developed by Vertanical has shown efficacy in phase 3 for chronic back pain and could reach its first markets soon.

News

Latigo raises $150m for non-opioid painkiller push

Latigo has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, raising $150 million in a Series B.

News

Taiho snaps up ADC partner Araris for up to $1.14bn

Taiho has reached a deal to buy Swiss biotech Araris, around 18 months after they started collaborating on antibody-drug conjugates for cancer.

News

AbbVie builds the case for ovarian cancer drug Elahere

AbbVie hopes for another lift to its fast-growing ovarian cancer drug Elahere with new survival data.

Sofinnova closes new fund and backs a trio of new biotechs

AstraZeneca buys cell therapy biotech for up to $1bn

Vertanical's cannabis-based painkiller hits target in trials

Latigo raises $150m for non-opioid painkiller push

Taiho snaps up ADC partner Araris for up to $1.14bn

AbbVie builds the case for ovarian cancer drug Elahere

Merck rare tumour drug Ezmekly backed for NHS use

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks